June 12, 2026
Argenica Therapeutics (ASX:AGN) completes final FDA requested assay for ARG-007
Argenica clears the final FDA safety assay for ARG-007 (xaranetide), paving the way for US clinical trials in acute stroke.
Category: Argenica Therapeutics
June 11, 2026
Argenica Therapeutics (ASX:AGN) secures INN for lead neuroprotective candidate
WHO confirms “xaranetide” as the International Nonproprietary Name for Argenica’s lead neuroprotective candidate, ARG-007.
December 13, 2025
Argenica Therapeutics (ASX:AGN) AI reanalysis sharpens efficacy signal for ARG 007 in severe stroke cohort
Dr Liz Dallimore, Managing Director of Argenica Therapeutics, spoke to MarketOpen about how an AI enabled reanalysis of the Phase 2 trial has clarified ARG 007’s efficacy in patients with severe acute ischaemic stroke.
April 11, 2025
Argenica Therapeutics (ASX:AGN) wraps up dosing in landmark stroke trial — Eyes 2025 for efficacy reveal
With all 92 stroke patients now treated, Argenica’s Phase 2 trial of ARG-007 heads into the critical data lock phase — and the biotech world is watching closely.
October 31, 2024
Argenica Therapeutics (ASX:AGN) strategic leap in neonatal brain protection gains FDA’s support
With FDA Orphan Drug and Rare Pediatric Disease designations, Argenica Therapeutics (ASX:AGN) strengthens its path forward for ARG-006, a promising treatment for neonatal brain injuries in hypoxic-ischaemic encephalopathy (HIE).
September 25, 2024
Argenica Therapeutics (ASX:AGN) poised for IND milestone: key safety studies propel ARG-007’s competitive edge
ARG-007’s unique mechanism of action and proven safety profile position it as a strong contender in the acute ischaemic stroke treatment landscape.
September 6, 2024
Argenica Therapeutics (ASX:AGN) pioneers breakthroughs in neuroprotection with ARG-007
Argenica Therapeutics is advancing its novel neuroprotective drug ARG-007 through a promising Phase 2 trial, with no adverse events reported and potential applications in multiple neurological conditions.
July 24, 2024
Argenica (ASX:AGN) continues on pace for pivotal Australian stroke trials
Pivotal trials which could position an Australian therapeutic as a leading candidate in the fight against stroke continue on pace.
May 15, 2024
Argenica (ASX:AGN) provides more proof of traumatic brain injury reduction
More preclinical data showing efficacy on an animal model has Argenica further on the path toward clinical trials for traumatic brain injury.
April 29, 2024
Argenica (ASX:AGN) stroke drug judged safe for continued efficacy testing
ARG-007 trials will continue unmodified across ten Australian hospitals after no adverse events in the first five patients.